Benefits of vitamin E supplementation to Norplant users — in vitro and in vivo studies

Subakir, Sri Bekti; Setiadi, Evi; Affandi, Biran; Pringgoutomo, Sudarto; Freisleben, Hans-Joachim

doi:10.1016/s0300-483x(00)00208-0

Cited by 26 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence also suggests that estrogen (154)(155)(156), daily COCs (154), LNG pills (155), tamoxifen (157), or tranexamic acid (158) can reduce the number of bleeding or spotting days during treatment among LNG implant users. In one small study, vitamin E was found to significantly reduce the mean number of bleeding days after the first treatment cycle; however, another larger study reported no significant differences in length of bleeding and spotting episodes with vitamin E treatment (159,160). Use of aspirin did not result in a significant difference in median length of bleeding or bleeding and spotting episodes after treatment (159).…”

Section: Bleeding Irregularities (Including Amenorrhea) During Implanmentioning

confidence: 96%

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Curtis

Jatlaoui²,

Tepper³

et al. 2016

MMWR Recomm. Rep.

342

351

View full text Add to dashboard Cite

The 2016 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a select group of common, yet sometimes controversial or complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, during August 26-28, 2015. The information in this report updates the 2013 U.S. SPR (CDC. U.S. selected practice recommendations for contraceptive use, 2013. MMWR 2013;62[No. RR-5]). Major updates include 1) revised recommendations for starting regular contraception after the use of emergency contraceptive pills and 2) new recommendations for the use of medications to ease insertion of intrauterine devices. The recommendations in this report are intended to serve as a source of clinical guidance for health care providers and provide evidence-based guidance to reduce medical barriers to contraception access and use. Health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.

show abstract

Section: Bleeding Irregularities (Including Amenorrhea) During Implanmentioning

confidence: 96%

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Curtis

Jatlaoui²,

Tepper³

et al. 2016

MMWR Recomm. Rep.

342

351

View full text Add to dashboard Cite

show abstract

“…Surprisingly, only few studies have investigated the effects of oral contraceptives (OCs) on the OS. Some studies showed a significant increase of lipid peroxides in women using subdermal implants of levonogestrel or injectable depo-medroxy progesterone acetate (DPMA) [16][17][18]. An increase of blood lipid peroxides was observed in rats treated with estro-progestative OCs [19] and a decrease of the liposoluble antioxidants coenzyme Q10 and -tocopherol was shown in women taking the OC compared to a control group not using OCs [20].…”

Section: Introductionmentioning

confidence: 99%

Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18–35 years old

et al. 2009

View full text Add to dashboard Cite

“…A series of clinical trials have been tried using different breakthrough bleeding management strategies associated with the use of implanon. This included the use of combined oral contraceptives, tranexamic acid, ethinyl estradiol, ibuprofen mefenamic acid and vitamin E. [15][16][17][18][19] It was found that the effects of the drugs mentioned above in reducing the duration of the days of bleeding more effective compared to the placebo. the effect of tamoxifen must be confirmed by a larger randomized controlled trial.…”

Section: Discussionmentioning

confidence: 99%

Tamoxifen for treatment of abnormal uterine bleeding in etonorgstrel implant users: a randomized clinical trial

Fetih

Abbas

Kamel³

et al. 2019

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: The current study aims to compare the use of tamoxifen and oral contraceptive pills in women using implanon and complain with irregular uterine bleeding.Methods: Women attended family planning clinic using implanon presented by bleeding were invited to participate in the study. They were randomized into two groups: Group A: 100 women received Tamoxifen 10 mg twice daily for 10 days taken at the onset of an episode of bleeding or spotting episode. Group B: 100 women received Combined oral contraceptive pills (microcept) once daily for 21 days take at the onset of an episode of bleeding or spotting episode.Results: No difference regarding the baseline criteria of both groups. No difference between both groups regarding the duration of irregular bleeding in the implanon users (p=0.090). Additionally, the number of bleeding days and spotting in the last month was similar in both groups (p=0.554). The percentage of women who stopped bleeding during the period of treatment is 84% in the tamoxifen group and 92% in the COCs group, but the COCs needs longer treatment time, where the mean of days required to stop bleeding is 5.03±1.8 days in the tamoxifen group and 6.5±2.5 in the COCs group. Headache and nausea were the most prominent adverse effects found in the COCs group (p=0.000).Conclusions: Oral administration of tamoxifen 10 mg twice daily for 10 days is effective on stopping bleeding attacks in implanon users.

show abstract

Benefits of vitamin E supplementation to Norplant users — in vitro and in vivo studies

Cited by 26 publications

References 6 publications

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18–35 years old

Tamoxifen for treatment of abnormal uterine bleeding in etonorgstrel implant users: a randomized clinical trial

Contact Info

Product

Resources

About